We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz Gets Third Approval for FOB in Europe
Sandoz Gets Third Approval for FOB in Europe
February 17, 2009
Sandoz has received final European Commission (EC) approval for its version of filgrastim, a follow-on biologic (FOB) of Amgen’s human granulocyte colony-stimulating factor Neupogen.